PBYI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Puma Biotechnology Inc (PBYI) is not a strong buy for a beginner, long-term investor at this moment. Despite a slight pre-market price increase and bullish moving averages, the lack of positive trading signals, insider and hedge fund selling, declining financial metrics, and no recent positive news or catalysts make this stock less appealing for immediate investment.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram (0.0733), indicating a potential upward trend. However, RSI is neutral at 49.294, and the stock is trading near its pivot level (7.27), suggesting limited momentum. Key resistance levels are at 7.789 and 8.109, while support levels are at 6.751 and 6.43.
The stock has shown a 27.72% YoY revenue increase in Q4 2025, and its bullish moving averages suggest potential price support.
Hedge funds and insiders are aggressively selling, with increases of 203.10% and 230.93%, respectively. Financial metrics such as net income (-30.39% YoY), EPS (-33.33% YoY), and gross margin (-9.28% YoY) have declined. No recent news or political trading data is available, and no Intellectia Proprietary Trading Signals are present.
In Q4 2025, revenue increased by 27.72% YoY to $75.45M. However, net income decreased by 30.39% YoY to $13.44M, EPS dropped by 33.33% to 0.26, and gross margin fell by 9.28% to 69.35%. These mixed results highlight growth in revenue but declining profitability.
No recent analyst ratings or price target changes are available for this stock.
